Brief: Baudax Bio Acquires Teraimmune, Inc.
30/06/2023 13:41
June 30 (Reuters) - Baudax Bio Inc BXRX.O :
* BAUDAX BIO ACQUIRES TERAIMMUNE, INC.
* BAUDAX BIO- ACQUISITION OF TERAIMMUNE WAS STRUCTURED AS A
STOCK-FOR-STOCK TRANSACTION
* BAUDAX EQUITY HOLDERS IMMEDIATELY PRIOR TO ACQUISITION
WILL OWN
APPROXIMATELY 18% OF COMBINED COMPANY
* ACQUISITION WAS UNANIMOUSLY APPROVED BY BOARD OF DIRECTORS
OF
BAUDAX AND BOARD OF DIRECTORS OF TERAIMMUNE
* BAUDAX BIO CEO GERRI HENWOOD TO SERVE AS CEO OF COMBINED
ENTITY
Source text for Eikon: ID:nGNX4whqsd
Further company coverage: BXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer